文献速递类风湿关节炎

类风湿关节炎患者多病共存负担与轨迹:2006至2015年匹配队列研究

Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015.
PubMed 文献 · Ann Rheum Dis · 2020-10-08

基于美国商业保险数据库的匹配回顾性队列研究显示,类风湿关节炎(RA)患者多病共存患病率(OR 2.29,95%CI 2.25-2.34)和负担(条件比1.68,95%CI 1.66-1.70)显著高于非RA人群。在新发RA队列中,RA患者慢性病累积速率显著更快(RA×随访年,β 0.21,95%CI 0.20-0.21,p<0.001)。结论建议在RA病程早期积极识别和干预多病共存。

要点

  • RA患者多病共存患病率和负担显著高于年龄性别匹配的非RA人群。
  • 新发RA患者慢性病累积速率显著快于非RA人群。
  • 应在RA病程早期积极识别和干预多病共存。

核心结论

  • 多病共存(≥2种慢性病)在RA中高度流行,且在RA发病期间及之后进展更快。

研究设计与样本

  • 匹配回顾性队列研究,使用2006至2015年美国大型商业保险数据库(MarketScan),按年龄和性别匹配RA患者与非RA患者,采用验证算法识别RA及44种预定义慢性病。

主要发现

  • 总体队列(n=277 782)中RA患者多病共存横断面患病率显著更高(OR 2.29,95%CI 2.25-2.34),负担亦更高(条件比1.68,95%CI 1.66-1.70)。
  • 新发RA亚队列(n=61 124)中RA患者慢性病数量多于非RA(β 1.13,95%CI 1.10-1.17),慢性病累积速率显著更快(RA×随访年,β 0.21,95%CI 0.20-0.21,p<0.001)。
  • 纳入RA前阶段及多项敏感性分析后结果相似。

关键数值与推荐

  • 多病共存定义为44种预识别慢性病中至少2种同时存在。

临床怎么用

  • 对RA患者应在病程早期积极筛查和管理多病共存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the onset and trajectory of multimorbidity between individuals with and without rheumatoid arthritis (RA). METHODS: A matched, retrospective cohort study was completed in a large, US commercial insurance database (MarketScan) from 2006 to 2015. Using validated algorithms, patients with RA (overall and incident) were age-matched and sex-matched to patients without RA. Diagnostic codes for 44 preidentified chronic conditions were selected to determine the presence (≥2 conditions) and burden (count) of multimorbidity. Cross-sectional comparisons were completed using the overall RA cohort and conditional logistic and negative binomial regression models. Trajectories of multimorbidity were assessed within the incident RA subcohort using generalised estimating equations. RESULTS: The overall cohort (n=277 782) and incident subcohort (n=61 124) were female predominant (76.5%, 74.1%) with a mean age of 55.6 years and 54.5 years, respectively. The cross-sectional prevalence (OR 2.29, 95% CI 2.25 to 2.34) and burden (ratio of conditions 1.68, 95% CI 1.66 to 1.70) of multimorbidity were significantly higher in RA than non-RA in the overall cohort. Within the incident RA cohort, patients with RA had more chronic conditions than non-RA (β 1.13, 95% CI 1.10 to 1.17), and the rate of accruing chronic conditions was significantly higher in RA compared with non-RA (RA × follow-up year, β 0.21, 95% CI 0.20 to 0.21, p<0.001). Results were similar when including the pre-RA period and in several sensitivity analyses. CONCLUSIONS: Multimorbidity is highly prevalent in RA and progresses more rapidly in patients with RA than in patients without RA during and immediately following RA onset. Therefore, multimorbidity should be aggressively identified and targeted early in the RA disease course.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. England BR, Roul P, Yang Y, et al. Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. Ann Rheum Dis. 2020. PMID: 33032999. doi:10.1136/annrheumdis-2020-218282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。